Browsing Pharmacology & Therapeutics (Scholarly Publications) by Title
Now showing items 6-25 of 38
-
A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer
(2013)Background: Preclinical evidence suggests a beneficial effect of metformin in colorectal cancer. This study aimed to investigate associations between metformin exposure and colorectal cancer–specific survival using ... -
Comparing primary prevention with secondary prevention to explain decreasing coronary heart disease death rates in Ireland 1985 - 2000
(2007)BACKGROUND: To investigate whether primary prevention might be more favourable than secondary prevention (risk factor reduction in patients with coronary heart disease(CHD)). METHODS: The cell-based IMPACT CHD mortality ... -
A competing risks prescription refill model of compliance and persistence.
(2010)Objectives There is evidence to suggest that noncompliant and nonpersistent behaviors have differing risk factors, clinical consequences, and responses to intervention. This has led to calls for these behaviors to be defined ... -
Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity
(Oxford University Press, 2008)Non-steroidal anti-inflammatory agents (NSAIDs) are associated with a marked reduction in the risk of developing Alzheimer's disease, a form of dementia characterized by the accumulation of amyloid plaques containing the ... -
DIFFERENTIAL INTERACTIONS OF ANTIRETROVIRAL AGENTS WITH LXR, ER AND GR NUCLEAR RECEPTORS - POTENTIAL CONTRIBUTING FACTORS OF ADVERSE EVENTS
(2014)BACKGROUND AND PURPOSE: Antiretroviral (ARV) drugs activate pregnane X receptors and constitutive androstane receptors, increasing the risk of drug interactions due to altered drug metabolism and disposition. The closely ... -
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis c virus genotype 1
(2013)Background. The licensing of direct-acting antivirals heralds a new era in the treatment of hepatitis C virus (HCV) genotype 1. We undertook a mixed treatment comparison to examine the relative efficacy among current ... -
Exosomes neutralize synaptic-plasticity-disrupting activity of Aß assemblies in vivo.
(2013)Abstract BACKGROUND: Exosomes, small extracellular vesicles of endosomal origin, have been suggested to be involved in both the metabolism and aggregation of Alzheimer's disease (AD)-associated amyloid β-protein (Aβ). ... -
Extracellular Forms of Aβ and Tau from iPSC Models of Alzheimer's Disease Disrupt Synaptic Plasticity
(2018)The early stages of Alzheimer’s disease are associated with synaptic dysfunction prior to overt loss of neurons. To identify extracellular molecules that impair synaptic plasticity in the brain, we studied the secretomes ... -
Fasting plasma glucose as initial screening for diabetes and prediabetes in irish adults: The diabetes mellitus and vascular health initiative (DMVhi)
(2015)OBJECTIVE: Type 2 diabetes has a long pre clinical asymptomatic phase. Early detection may delay or arrest disease progression. The Diabetes Mellitus and Vascular health initiative (DMVhi) was initiated as a prospective ... -
GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo
(2010)Currently, treatment with the relatively low-affinity NMDA receptor antagonist memantine provides limited benefit in Alzheimer's disease (AD). One probable dose-limiting factor in the use of memantine is the inhibition of ... -
Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances
(2012)The cognitive and related symptoms of Alzheimer's disease are mainly attributable to synaptic failure. Here we review recent research on how the Alzheimer's disease amyloid ?-protein (A?) affects glutamate receptors and ... -
Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study.
(2015)ACKGROUND: Recent advances in Hepatitis C therapeutics offer the possibility of cure but will be expensive. The cost of treatment may be partially offset by the avoidance of advanced liver disease. We performed a ... -
Interaction between prion protein and toxic amyloid ß assemblies can be therapeutically targeted at multiple sites.
(2011)A role for PrP in the toxic effect of oligomeric forms of A?, implicated in Alzheimer's disease (AD), has been suggested but remains controversial. Here we show that PrP is required for the plasticity-impairing effects of ... -
Medicinal plants used by traditional medicine practitioners for the treatment of HIV/AIDS and related conditions in Uganda
(Elsevier, 2010)Introduction and objectives: In Uganda, there are over 1 million people with HIV/AIDS. When advanced, this disease is characterized by life-threatening opportunistic infections. As the formal health sector struggles to ... -
MGlu5 receptors and cellular prion protein mediate amyloid-ß- facilitated synaptic long-term depression in vivo
(2014)NMDA-type glutamate receptors (NMDARs) are currently regarded as paramount in the potent and selective disruption of synaptic plasticity by Alzheimer's disease amyloid β-protein (Aβ). Non-NMDAR mechanisms remain relatively ... -
Modelling Coronary Heart Disease Mortality declines in the Republic of Ireland, 1985-2006
(2013)BACKGROUND: Consistent declines in coronary heart disease (CHD) death rates have been previously observed in Ireland since 1985. AIMS & METHODS: To use the previously validated Irish IMPACT CHD mortality model to ... -
A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer
(2013)Background: Non-persistence and non-compliance are common in women prescribed hormonal therapy for breast cancer, but little is known about their influence on recurrence. Methods: A nested case–control study of ... -
Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease Aß in vivo.
(2014)Many endogenous factors influence the time course and extent of the detrimental effects of amyloid β-protein (Aβ) on synaptic function. Here, we assessed the impact of varying endogenous glutamatergic and cholinergic ... -
Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer's disease Aß synaptotoxicity
(2014)Alzheimer's disease (AD) is associated with pathological assembly states of amyloid-β protein (Aβ). Aβ-related synaptotoxicity can be blocked by anti-prion protein (PrP) antibodies, potentially allowing therapeutic targeting ...